A study found reduced chaperone-mediated autophagy in spinal motor neurons affected by ALS
Original source
Chaperone mediated autophagy is deficient in spinal motoneurons of ALS patients with TDP-43 proteinopathy. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Related topics
Researchers found lower levels of LAMP2A, a marker of chaperone-mediated autophagy (CMA), in spinal motor neurons from people with sporadic ALS and TDP-43 pathology. The affected neurons also contained TDP-43 aggregates, while relatively resistant neurons retained normal LAMP2A levels and lacked these aggregates. The findings suggest that impaired CMA may contribute to TDP-43 accumulation in ALS.
Why this matters
The study identifies CMA as a possible mechanism involved in motor-neuron vulnerability and suggests that increasing CMA could be investigated as a treatment strategy. However, this work examined human tissue and does not show that changing CMA improves symptoms, slows ALS, or is safe in people; it does not change treatment now.
Limitations and context
This was a tissue-based study measuring molecular markers in spinal cords, not a clinical trial. The source summary does not provide the number or clinical details of the samples. The findings show an association between reduced LAMP2A, CMA-related changes and TDP-43 pathology, but do not by themselves prove that CMA impairment causes neuron loss or that CMA-enhancing treatments will work. The article was published as a primary research journal article; the source does not indicate whether the findings have been independently replicated.